Our scientists and oncologists strive to give patients improved treatment outcomes and a life beyond cancer by developing therapies that elevate the standards of care.
Our scientific research has led to critical discoveries in the treatment of blood cancer. Building upon our strong commitment to patients and existing leadership in blood cancers, we are now boldly expanding our footprint in solid tumors. Our robust portfolio in blood cancers and solid tumors is comprised of first-of-its kind treatments and an advancing pipeline of more than 20 investigational assets that are designed to tackle some of the most difficult-to-treat cancers in the world.
We focus on creating targeted medicines that either impede the reproduction of cancer cells or enable their death. We achieve this through multiple modalities such as immuno-oncology approaches, tumor antigen targeting, and taking advantage of specific tumor dependencies. Our research interests include:
We are focusing on finding answers that transform the way cancer are treated. We want to find better, longer-lasting results across blood cancers and solid tumors. Our culture of curiosity drives us to uncover new solutions.
Blood cancer is a disease that impacts blood forming tissues (such as bones marrow) and inhibits the body's ability to fight off infection. Leukemia, lymphoma, and myeloma are the most common forms of blood cancer that are seen in patients.
Despite recent innovations, people living with solid tumors are still in need of more options. As survival rates remain low, patients often run out of options after multiple cycles of treatment, emphasizing the urgent need to further improve patient care and outcomes.
We are advancing an innovative solid tumor portfolio that tackles some of the most difficult-to-treat cancers. Our approach is to target novel anti-cancer pathways, using different modalities such as antibody-drug conjugates (ADCs) designed to target protein biomarkers, which are over-expressed across various tumor types, to deliver potent cancer-killing agents called ‘payloads’ to those cells, and immuno-oncology (IO) approaches, that use the body's immune system to fight cancer.
The product-specific site Internet site that you have requested is intended for the residents of a particular country or countries, as noted on that site. As a result, the site may contain information on pharmaceuticals that are not approved in other countries or region. If you are a resident of a country other than those to which the site is directed, please return to AbbVie.com or contact your local AbbVie affiliate to obtain the appropriate product information for your country of residence. The Internet site that you have requested may not be optimized to your screen size. Do you wish to continue to this product-specific site?